drugset / Trial / NCT03029585
Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will evaluate NanoPac® administered intraperitoneally (IP) immediately post-cytoreductive surgery, followed by standard of care (SOC) intravenous (IV) chemotherapy, in women with ovarian cancer. The study will compare IP NanoPac® (plus IV chemotherapy) with SOC IV chemotherapy alone.
Timeline
- Start
- 2017-04-19
- Primary completion
- 2019-11-04
- Completion
- 2019-11-04
Outcome
Outcome not reported
Stopped (Business): “Business reasons”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NanoPac® | Unknown | 100 mg/m2 | Other |
| Subject | NanoPac® | Unknown | 200 mg/m2 | Other |
| Subject | NanoPac® | Unknown | 300 mg/m2 | Other |
| Subject | NanoPac® | Unknown | 400 mg/m2 | Other |
| Background | Carboplatin | Small molecule | — | Intravenous |
| Background | Paclitaxel | Small molecule | — | Intravenous |